Ceremedix

Ceramedix is a preclinical-stage biopharmaceutical company headquartered in New York City, focused on developing a novel class of antibody-based therapeutics to treat diseases driven by microvascular injury. The company's core technology platform targets "ceramide-rich platforms" (CRPs), which are unique lipid clusters that form on the surface of injured endothelial cells and trigger cell death (apoptosis). By utilizing proprietary anti-ceramide antibodies, such as its lead candidate CX-01, Ceramedix aims to disrupt these platforms and restore microvascular homeostasis. The company is initially advancing programs for diabetic retinopathy, diabetic macular edema, and gastrointestinal acute radiation syndrome (GI-ARS), with additional research into kidney and lung diseases. Ceramedix is a resident of JLABS and has secured significant funding from the NIH and private investors like Hibiscus Capital Management.